Location Directory

Clinical trials in Cleveland, Ohio

This page shows live ClinicalTrials.gov search results for Cleveland, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 4:24 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

11328

Shown on this page

Current sort

Institutions in Cleveland

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Cleveland Clinic

Live official records

Open in full search

Conditions: Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM), Glioma, Central Nervous System Diseases, Brain Cancer
Interventions: silevertinib in combination with temozolomide, temozolomide (TMZ); Drug
Lead sponsor: Black Diamond Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 38
States / cities: Birmingham, Alabama • Springdale, Arkansas • La Jolla, California + 33 more

Conditions: Focal Epilepsy, Tonic-Clonic Seizures
Interventions: XEN1101; Drug
Lead sponsor: Xenon Pharmaceuticals Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 54
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 48 more

Conditions: Migraine
Interventions: Elismetrep, Placebo; Drug
Lead sponsor: TriGemX Bio, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 72
States / cities: Glendale, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 64 more

Conditions: Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Carcinoma
Interventions: Capecitabine, Carboplatin, Cisplatin, Etoposide, Laboratory Biomarker Analysis, Temozolomide; Drug · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2029
U.S. locations: 673
States / cities: Kingman, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 431 more

Conditions: Clostridoides Difficile Associated Disease
Interventions: C.difficile vaccine, Saline Placebo; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years and older
Enrollment: 32,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 142
States / cities: Athens, Alabama • Guntersville, Alabama • Huntsville, Alabama + 90 more

Conditions: Advanced Solid Tumor, Mesothelioma, Malignant
Interventions: SW-682, Combination Therapy; Drug
Lead sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany; Industry
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Scottsdale, Arizona • Los Angeles, California • Sacramento, California + 5 more

Conditions: CRC (Colorectal Cancer)
Interventions: INCA33890, Placebo, Bevacizumab, FOLFOX; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 78
States / cities: Mobile, Alabama • Tucson, Arizona • Fountain Valley, California + 65 more

Conditions: Solid Tumors
Interventions: INCB161734, Placebo, Investigator's choice of chemotherapy; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 69
States / cities: Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 55 more

Conditions: Aphakia, Astigmatism
Interventions: Clareon TruPlus Monofocal Non-Toric IOL, Clareon TruPlus Monofocal Toric IOL, Phacoemulsification; Device · Procedure
Lead sponsor: Alcon Research; Industry
Eligibility: 22 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Phoenix, Arizona • Brecksville, Ohio • Mt. Pleasant, South Carolina + 2 more

Conditions: Breast Cancer
Interventions: Living Cancer CALM education intervention; Behavioral
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy
Interventions: TAK-861, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 11
States / cities: Redwood City, California • Brandon, Florida • Miami, Florida + 8 more

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: mezigdomide, Pomalidomide, Bortezomib, Dexamethasone; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 810 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 56
States / cities: Los Alamitos, California • San Diego, California • West Hollywood, California + 50 more

Clinical trials in Cleveland, Ohio

Filter and sort this location

Institutions in Cleveland

Live official records

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

An Open-label Study of XEN1101 in Epilepsy

A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older

SW-682 in Advanced Solid Tumors

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

Clareon TruPlus Study

Culinary And Lifestyle Medicine Education for Cancer Risk Reduction in Survivors of Breast Cancer

A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)